mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. - Wikidata - awgldk - TriplyDB

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.

http://www.wikidata.org/entity/Q38907215

about

Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma.Transducin (β)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway.Pigment epithelium-derived factor promotes tumor metastasis through an interaction with laminin receptor in hepatocellular carcinomas.DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway.A platform of BRET-FRET hybrid biosensors for optogenetics, chemical screening, and in vivo imaging.

P2860

Q26745311-9A07FC30-D34B-4C2C-A200-944E6A8B7F24 Q37190236-27B57CBD-3F48-44CC-AA70-3C9AF8456235 Q37301884-8A8FC0E2-FC3F-42DE-AA5B-C07BF9AD6CBD Q37465944-E9BB1239-6925-4ADE-B73B-7DE0244F2CEC Q37736264-7405D98D-D011-446F-AD9F-630F0584BAFB Q41169776-70B56E01-ECC7-44C4-A7E3-5BBDC6666370 Q54979427-FDCB0678-2221-4764-8D90-DDD890738904 Q55380056-2D31511A-8DA3-46EE-981E-7C10D23DCD07

P2860

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.

http://www.wikidata.org/entity/Q38907215

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

mTORC1 upregulation via ERK-de ...... enic KRas-mutant cancer cells.

@en

type

label

mTORC1 upregulation via ERK-de ...... enic KRas-mutant cancer cells.

@en

prefLabel

mTORC1 upregulation via ERK-de ...... enic KRas-mutant cancer cells.

@en

P1433

Q38907215-0D8AEFDB-D68B-4811-A2B1-3173174600A5

P1476

Q38907215-545286DD-1E82-41D0-981B-E042FAA01421

P2093

Q38907215-34E94732-0E6B-490B-AE83-206A2037747E

Q38907215-B057DF8A-A042-4BF1-BAC9-BE7A94083FB8

P2860

Q38907215-06123A10-D221-42C6-82FD-1B12A5DE334A

Q38907215-08B2461D-4D9A-49DC-A8A9-C9B52B8A53A4

Q38907215-1030AABB-EF4E-4DCF-B2A1-38DCAC7EB580

Q38907215-17CA743E-F2D9-44D7-B466-67897D5E7E2B

Q38907215-1FCFBBFF-F273-4005-B624-900416EE98EF

Q38907215-23DA81C7-E13B-4EE6-84C4-8D246E5AF6F1

Q38907215-2E6B0D90-64AB-4990-991B-EE7A1107F181

Q38907215-30344F1F-1E21-4469-AA57-43C59C5D302E

Q38907215-31B69DF6-5E33-4E18-823F-3F7C52E44AC8

Q38907215-3D1F1486-D12B-4B9E-8D5D-B72FF5910877

P2888

Q38907215-0DEE32C5-4FE3-46BA-9772-66460AE669EA

P304

Q38907215-F7B0B557-1BCD-4773-A290-B8AED078BE6C

P31

Q38907215-EF6D74F1-BB03-4D37-B344-D26271C67899

P356

Q38907215-6E9A8F03-F468-4AA7-91C4-B881BC4AF495

P407

Q38907215-2D35FA04-D6BB-4CCA-99EC-816E913AD3B7

P433

Q38907215-160EDC4F-0EAE-413A-B6E0-16173715469A

P478

Q38907215-D4BD129D-A65B-4990-955F-E7B83EE01A3B

P50

Q38907215-011FB446-F503-4755-B85E-AA5ECFEF110D

Q38907215-05F2A2CD-71CD-4C5E-AACB-18474CAB1280

P577

Q38907215-F4B7BFAB-2BFF-4517-A3ED-29038FBBDDE7

P6179

Q38907215-18FD7DB3-57FC-4FEB-918E-DA778624FE0A

P698

Q38907215-DC79EF4E-4D1C-4AC9-9699-D39BBCAE3A5E

P356

P1433

P1476

mTORC1 upregulation via ERK-de ...... genic KRas-mutant cancer cells

@en

P2093

N Komatsu

http://www.w3.org/2001/XMLSchema#string

Y Fujita

http://www.w3.org/2001/XMLSchema#string

P2860

Mapping and quantifying mammalian transcriptomes by RNA-Seq

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

RAS oncogenes: weaving a tumorigenic web

Cancer. Addiction to oncogenes--the Achilles heal of cancer

BRAF mutation predicts sensitivity to MEK inhibition

P2888

P304

5607-5616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2015.16

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Michiyuki Matsuda

P577

2015-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036409827

http://www.w3.org/2001/XMLSchema#string

P698

25703330

http://www.w3.org/2001/XMLSchema#string